A one-day event offering access to the latest research and clinical advancements in respiratory medicine. Attend in person or access it online as a virtual delegate
ERS Respiratory Updates is a one-day event for respiratory professionals who are/were unable to attend the ERS International Congress but who want to keep their practice and knowledge up-to-date and at ‘the cutting edge’.
The event will consist of comprehensive clinical updates across the 8 disease areas. It will give you access to the most current thinking in respiratory clinical medicine, including news, findings and medical advances from the latest ERS International Congress.
The clinical updates will be delivered by prominent international experts in each field and will be followed by a networking lunch which will allow you to explore these topics further.
Join us for ERS Respiratory Updates – be at the cutting edge
Amsterdam: 8 November, 2019 (delivered in English)
- Chairs: Daiana Stolz and Guy Brusselle
- Each speaker will present for 25 minutes, followed by 15 minutes for questions
Note: you can also be a virtual delegate with our online access option
Accessible for all respiratory professionals
This event is 35€ to attend in person and free to all respiratory professionals joining us online.
How to register
Attend in person: to register to attend in person please use the blue REGISTER button located in the bottom right corner of this webpage. Early registration is advised as spaces are limited. Please note that the registration fee is 35€. This amount is non-refundable. Registration will open soon.
Join us online: Registration will open soon.
Earn CME credits
An application will be made to EBAP for CME accreditation of this event.
The amount of credits you can receive will correspond to your attendance on the day. Note that you will need to sign the attendance list on site to ensure that you receive the CME credits.
If you have any queries, please contact firstname.lastname@example.org
This event is organised by ERS with funding support from AstraZeneca, GlaxoSmithKline and Novartis.